Ciltacabtagene autoleucel
- Generic Name
- Ciltacabtagene autoleucel
- Brand Names
- Carvykti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 0L1F17908Q
- Background
Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000, and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience a range of symptoms including bone pain, hematologic abnormalities, and end-org...
- Indication
Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT06623630
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05767359
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.